Dark

Check out our Dark Pool Levels

ABOS
Acumen Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Market Open

Jul 28, 2026 1:12:35 PM EDT

2.33USD+5.909%(+0.13)497,399

2.32Bid 2.33Ask 0.01Spread

Pre-market

Jul 27, 2026 9:22:30 AM EDT

2.15USD+0.939%(+0.02)0

After-hours

Jul 27, 2026 4:00:30 PM EDT

2.20USD-0.452%(-0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 21, 2022

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022 Benzinga

07:01AM EST B of A Securities Upgrades Acumen Pharmaceuticals to Buy, Lowers Price Target to $14 Benzinga

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Nov 15, 2021

11:03AM EST Acumen Pharmaceuticals Q3 Net Loss $3.9M Benzinga

08:22AM EST Acumen Pharma Q3 Net Loss $3.9 Mln Vs Loss $2.5 Mln Last Year RTTNews

08:00AM EST Acumen Pharmaceuticals Reports Financial Results for Third Quarter GlobeNewswire Inc

Nov 8, 2021

08:00AM EST Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimers disease (AD), today announced that the company will participate in the following upcoming virtual conferences: GlobeNewswire Inc

Nov 2, 2021

10:57AM EDT Acumen Pharmaceuticals To Present Clinical Trial Design For INTERCEPT-AD Phase 1 Placebo-Controlled, Single-And Multiple-Dose Clinical Trial Of ACU193, At 2021 Clinical Trials On Alzheimer's Disease (CTAD) Conference Nov. 9-12 Benzinga

08:00AM EDT ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AOs) GlobeNewswire Inc

Oct 7, 2021

08:03AM EDT Acumen Announces First Patient Dosed In A Phase 1 Clinical Trial Of ACU193, A Monoclonal Antibody That Selectively Targets Toxic A Oligomers For The Treatment Of Early Alzheimer's Disease Benzinga

08:00AM EDT ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AOs) GlobeNewswire Inc

Aug 16, 2021

04:05PM EDT Acumen Pharmaceuticals Reports Financial Results GlobeNewswire Inc

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 26, 2021

10:37AM EDT UPDATE: Credit Suisse On Acumen Outperform Initiation: Firm Highlights Differentiated Amyloid Beta Approach For Alzheimer's Disease With ACU193 Targeting Oligomers; Warns On Non-Targeting Approach Towards Plaque & Expects 15% Probability Of Success Benzinga

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021 Benzinga

09:19AM EDT UBS Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $27 Benzinga

08:52AM EDT B of A Securities Initiates Coverage On Acumen Pharmaceuticals with Neutral Rating, Announces Price Target of $20 Benzinga

08:35AM EDT Credit Suisse Initiates Coverage On Acumen Pharmaceuticals with Outperform Rating, Announces Price Target of $26 Benzinga

08:12AM EDT Stifel Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $27 Benzinga

Jul 13, 2021

06:17PM EDT Last IPO Week Was The Busiest In Over A Decade Benzinga

05:59PM EDT A Shortened IPO Holiday Week Benzinga

Jul 11, 2021

05:10PM EDT The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More Benzinga

Jul 1, 2021

10:58AM EDT Acumen Pharmaceuticals Shares Open For Trade At $25.07; IPO Priced At $16/Share Benzinga

09:35AM EDT Acumen Pharmaceuticals Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT: IPO Priced At $16/Share Benzinga

Jun 30, 2021

10:45PM EDT Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public GlobeNewswire Inc

Share